PFM Health Sciences’s Incyte INCY Stock Holding History

PFM Health Sciences’s Portfolio INCY Stock Details INCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-409,000	Closed	-$47.7M	–	86
2017 Q3	$47.7M	Buy	+409,000	New	+$51.7M	0.94%	42

Other funds holding INCY

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PFM Health Sciences's INCY Position: Q1 2022 in Review

PFM Health Sciences sold out of Incyte (INCY) in Q1 2022, closing a stake of 129,428 shares — an estimated $9.5M sold.

PFM Health Sciences first reported a position in INCY in Q4 2021 and held it in 1 quarter. The position peaked at $9.5M in Q4 2021. 533 funds tracked by Wall St. Rank hold INCY as of Q1 2022.

PFM Health Sciences reported no remaining Incyte position as of Q1 2022 after selling out during the quarter.
PFM Health Sciences sold 129,428 Incyte shares in Q1 2022, an estimated $9.5M.
PFM Health Sciences first reported a position in Incyte in Q4 2021 and held it in 1 quarter.
PFM Health Sciences's Incyte position peaked at $9.5M in Q4 2021.
533 funds tracked by Wall St. Rank held Incyte as of Q1 2022.

Based on PFM Health Sciences's 13F filing for Q1 2022, filed 16 May 2022.